hotspot -WSS

hotspot

author：knowledge 2025-09-28 22:53:45 - browse：83939

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

explore

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

STAT Summit: Ending the crisis of Black deaths in the U.S.

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

ADCs take center stage as promising cancer treatments

The problems with dementia villages

STAT Summit: Meghan O’Rourke on making chronic illness visible

focus

hotspot

explore

Virginia high school admissions case could be legal follow

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Cancer drug shortages should be causing more outrage

Morphosys mixed study results for blood cancer drug

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Novavax promises a turnaround & Lilly roils the obesity market

Childhood cancer progress stalls for Black, Hispanic kids: Report

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD podcast: Live from the 2023 STAT Summit

Wikipedia

PBM reforms clear House panel

NYU radiologists take on the challenge of expensive MRI machines

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Hospitals look to new technology to keep health care workers safe

Does good food count as health care? Study aims to find out

knowledge

explore

focus

hotspot